Why the study?
Does abciximab cause acute profound thrombocytopenia in patients undergoing percutaneous coronary revascularization?
Does abciximab cause acute profound thrombocytopenia in patients undergoing percutaneous coronary revascularization?
Abciximab administration during percutaneous coronary revascularization can cause unpredictable acute profound thrombocytopenia, highlighting the need for platelet count monitoring 2 to 4 hours post-bolus.
No takes yet. Share an insight, caveat, or question.
Abciximab may cause acute profound thrombocytopenia; leaves open optimal monitoring protocols pending larger prospective data.
Berkowitz et al. (1997) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: